Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:35:24 2023-01-26 am EST
89.72 EUR   -0.21%
01/25Press Release : NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
GL
01/25Press Release : NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
AQ
01/25Biopharma, Tech Stocks Lead European Equities Slightly Lower
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SANOFI : Credit Suisse remains its Buy rating

11/30/2022 | 08:52am EST

Credit Suisse analyst Dominic Lunn maintains his Buy rating on the stock. The target price is unchanged at EUR 106.


ę MarketScreener with dpa-AFX Analyser 2022
All news about SANOFI
01/25Press Release : NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating i..
GL
01/25Press Release : NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating i..
AQ
01/25Biopharma, Tech Stocks Lead European Equities Slightly Lower
MT
01/25Denali Therapeutics Says Partner Sanofi Starts Patient Dosing in Phase 2 Multiple Scler..
MT
01/25Sanofi Commences Dosing in a Phase 2 Study of SAR443820 in Individuals with Multiple Sc..
CI
01/25CAC 40 Falls At Midday As December 2022 Data Shows Growth In French Unemployment
MT
01/25Innate Pharma Secures Antitrust Clearance for Expansion of Oncology Collaboration With ..
MT
01/25SANOFI : Receives a Buy rating from Goldman Sachs
MD
01/25SANOFI : Barclays reiterates its Neutral rating
MD
01/25Innate Pharma's Licensing Deal With Sanofi On Natural Killer Cell Engager Program Takes..
MT
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2022 43 551 M 47 262 M 47 262 M
Net income 2022 7 376 M 8 004 M 8 004 M
Net Debt 2022 7 473 M 8 110 M 8 110 M
P/E ratio 2022 15,5x
Yield 2022 3,96%
Capitalization 112 B 121 B 121 B
EV / Sales 2022 2,74x
EV / Sales 2023 2,56x
Nbr of Employees 95 442
Free-Float 87,9%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 89,72 €
Average target price 107,05 €
Spread / Average Target 19,3%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI0.08%122 159
JOHNSON & JOHNSON-4.72%443 181
ELI LILLY AND COMPANY-5.32%332 306
NOVO NORDISK A/S1.07%313 303
ROCHE HOLDING AG1.07%281 267
MERCK & CO., INC.-2.13%275 319